Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Maintains Clinical Trial Coverage Status Quo

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency backs down from changes proposed in July, in part because of provisions in recently passed FDA reform act.

You may also be interested in...

Reimbursement In Brief

CMS drops reimbursement code for off-label Avastin use ahead of schedule: On Nov. 16, CMS formally drops the Q-code it had set up to reimburse physicians outside of the hospital setting for off-label use of Avastin (bevacizumab) to treat wet aged macular degeneration. The agency previously announced the Q-code would be dropped on Jan. 1, 2010 (1"The Pink Sheet" DAILY, Oct. 28, 2009). The Q-code generated controversy because it would under-reimburse physicians who use the drug over Lucentis (ranibizumab), which is approved for the indication but is significantly more expensive. Both drugs are manufactured by Roche/Genentech

Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term

The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts